Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 73rd Annual Meeting of the American College of Rheumatology
Update on Interleukin-6 Antagonism in Rheumatoid Arthritis
Philadelphia, Pennsylvania / October 17-21, 2009
Philadelphia - Blocking inflammation via various inflammatory pathways with biologic therapy has dramatically improved outcomes for patients with rheumatoid arthritis. Results from a clinical trials program on the novel interleukin-6 (IL-6)...
MEDICAL OPTIONS - Pain Management
Putting Risk in Perspective: Selective and Non-selective NSAIDs - Reviews from published literature
September 2009
SELECTING NSAIDs IN OSTEOARTHRITIS: A PRACTICAL APPROACH Editorial Review: Algis V. Jovaisas, MD, FRCPC Assistant Professor of Medicine, Division of Rheumatology, University of Ottawa, Ottawa, Ontario Many factors conspire to emphasize the...
PRIORITY PRESS - 10th Annual European Congress of Rheumatology (EULAR)
Achieving and Maintaining Remission in RA: Long-term Data on IL-6 Inhibition
Copenhagen, Denmark / June 10-13, 2009
Copenhagen - In the management of rheumatoid arthritis (RA), achieving and maintaining clinical remission and attenuating the risk of increasing disability are among the most important treatment goals. With sustained clinical remission,...
ABSTRACTS in PERSPECTIVE based on presentations from the 10th Annual European Congress of Rheumatology (EULAR)
Inflammation Control in Rheumatoid Arthritis Through Interleukin-6 Inhibition
Copenhagen, Denmark / June 10-13, 2009
EDITORIAL OVERVIEW: Alfred A. Cividino, MD, FRCPC, Clinical Professor of Medicine, Division of Rheumatology, McMaster University, Hamilton, Ontario If inflammation over time equals joint damage, then timely control of rheumatoid arthritis...
PRIORITY PRESS - British Society for Rheumatology and British Health Professionals in Rheumatology Annual Conference
IL-6 Receptor Inhibition in Rheumatoid Arthritis: New Insights from Clinical Trials
Glasgow, UK / April 28-May 1, 2009
Glasgow - Between 30% and 40% of patients with rheumatoid arthritis (RA) fail to respond to currently available disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents, creating a need for new agents that target novel...
PHYSICIAN PERSPECTIVE Viewpoint based on presentations from the 64th Annual Meeting of the Canadian Rheumatology Association
Long-term Effectiveness of Tumour Necrosis Factor Inhibitors in the Treatment of Psoriatic Arthritis
Kananaskis, Alberta / February 18-21, 2009
INTRODUCTION Psoriatic arthritis (PsA) is a chronic progressive inflammatory disease that affects both the skin and the joints. More severe forms can lead to progressive joint destruction and bony fusion with patients experiencing...
FRONTLINE - Based on Sessions from the 64th Annual Meeting of the Canadian Rheumatology Association
Rheumatology
Kananaskis, Alberta / February 18-21, 2009
Spondyloarthropathies and Comorbidities: Enhancing Patient Care by Increasing Interspecialty Awareness Editorial Overview: Michel Zummer, MD, FRCPC Head, Division of Rheumatology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec The...
ABSTRACTS in PERSPECTIVE based on presentation from the 72nd Annual Meeting of the American College of Rheumatology
Perspectives on IL-6 Inhibition in Rheumatoid Arthritis: An Analysis of Recent Data
San Francisco, California / October 24-29, 2008
EDITORIAL OVERVIEW: Louis Bessette, MD, MSc, FRCPC Clinical Professor, Department of Medicine, Université Laval, Rheumatologist, CHUQ-Centre hospitalier de l’Université Laval, Quebec City, Quebec Biologic therapy for rheumatoid arthritis...
ABSTRACTS in PERSPECTIVE based on presentations from the 72nd Annual Meeting of the American College of Rheumatology
The Case for Early Combination Therapy in Rheumatoid Arthritis: Reviewing the TNF Inhibition Evidence to Date
San Francisco, California / October 24-29, 2008
EDITORIAL REVIEW: Michael R. Starr, MD, FRCPC Division of Rheumatology, Montreal General Hospital, Assistant Professor of Medicine, McGill University, Montreal, Quebec Rheumatoid arthritis (RA) affects more than 2 million adults in the US,...